Display options
Cite
Ebron JS, Weyman CM, Shukla GC. Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer. J Cancer Ther. 2013;4(4):47-58doi: 10.4236/jct.2013.44A006.
Ebron, J. S., Weyman, C. M., & Shukla, G. C. (2013). Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer. Journal of cancer therapy, 4(4), 47-58. https://doi.org/10.4236/jct.2013.44A006
Ebron, Jey Sabith, et al. "Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer." Journal of cancer therapy vol. 4,4 (2013): 47-58. doi: https://doi.org/10.4236/jct.2013.44A006
Ebron JS, Weyman CM, Shukla GC. Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer. J Cancer Ther. 2013 Apr;4(4):47-58. doi: 10.4236/jct.2013.44A006. PMID: 26877888; PMCID: PMC4751888.
Copy Download .nbib Format: NLM
Share it on

J Cancer Ther. 2013 Apr;4(4):47-58. doi: 10.4236/jct.2013.44A006.

Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer.

Journal of cancer therapy

Jey Sabith Ebron, Crystal M Weyman, Girish C Shukla

Affiliations

  1. Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, USA.
  2. Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, USA; Department of Biological, Environmental Sciences, Cleveland State University, Cleveland, USA.

PMID: 26877888 PMCID: PMC4751888 DOI: 10.4236/jct.2013.44A006

Abstract

Prostate cancer begins as an androgen-responsive disease. However, subsequent accumulation of multiple sequential genetic and epigenetic alterations transforms the disease into an aggressive, castration-resistant prostate cancer (CRPC). The monoallelic Androgen Receptor (AR) is associated with the onset, growth and development of Prostate cancer. The AR is a ligand-dependent transcription factor, and the targeting of androgen- and AR-signaling axis remains the primary therapeutic option for Prostate cancer (PCa) treatment. A durable and functional disruption of AR signaling pathways combining both traditional and novel therapeutics is likely to provide better treatment options for CRPC. Recent work has indicated that expression of AR is modulated at the posttranscriptional level by regulatory miRNAs. Due to a relatively long 3' untranslated region (UTR) of AR mRNA, the posttranscription expression is likely to be regulated by hundreds of miRNAs in normal as well as in disease state. The main objective of the article is to offer a thought-provoking concept of "andro-miRs" and their potential application in AR gene expression targeting. This new paradigm for targeting constitutively active AR and its tumor specific splicing isoforms using andro-miRs may pave the way for a novel adjunctive therapy and improved treatment of CRPC.

Keywords: 3’ Untranslated Region; Andro-miR; Androgen Receptor; Castration-Resistant Prostate Cancer (CRPC); Prostate Cancer; microRNA

References

  1. Cancer Res. 2009 Apr 15;69(8):3356-63 - PubMed
  2. Cancer Res. 2013 Jan 15;73(2):483-9 - PubMed
  3. Prostate. 2012 Oct 1;72(14):1514-22 - PubMed
  4. Cancer Cell Int. 2005 Apr 06;5(1):8 - PubMed
  5. Mol Cell Endocrinol. 2001 Jun 20;179(1-2):105-9 - PubMed
  6. Nat Med. 2004 Jan;10(1):33-9 - PubMed
  7. J Pathol. 2002 Oct;198(2):237-44 - PubMed
  8. J Biol Chem. 2012 Jun 1;287(23):19736-49 - PubMed
  9. Urol Res. 2000 Aug;28(4):211-9 - PubMed
  10. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2889-94 - PubMed
  11. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 - PubMed
  12. Nature. 2005 Jun 9;435(7043):839-43 - PubMed
  13. J Biol Chem. 2007 Jan 12;282(2):1479-86 - PubMed
  14. J Biol Chem. 2003 Feb 14;278(7):5052-61 - PubMed
  15. Hum Mutat. 2012 May;33(5):887-94 - PubMed
  16. Trends Endocrinol Metab. 2002 Aug;13(6):234-9 - PubMed
  17. Endocr Relat Cancer. 2004 Mar;11(1):117-30 - PubMed
  18. J Biol Chem. 2009 Sep 11;284(37):24696-704 - PubMed
  19. Cell. 2005 Jan 14;120(1):15-20 - PubMed
  20. Mol Endocrinol. 1991 Oct;5(10):1396-404 - PubMed
  21. Mol Cell. 2004 Sep 24;15(6):937-49 - PubMed
  22. Science. 2009 May 8;324(5928):787-90 - PubMed
  23. Br J Cancer. 2006 Mar 27;94(6):776-80 - PubMed
  24. Prostate. 2007 Dec 1;67(16):1801-15 - PubMed
  25. PLoS One. 2008 May 21;3(5):e2236 - PubMed
  26. Science. 1995 Nov 24;270(5240):1354-7 - PubMed
  27. Genes Dev. 2000 Oct 15;14(20):2551-69 - PubMed
  28. PLoS One. 2012;7(3):e32832 - PubMed
  29. Mol Cancer Ther. 2005 Apr;4(4):505-15 - PubMed
  30. J Biol Chem. 1991 Jun 15;266(17):10743-9 - PubMed
  31. Nature. 2008 Sep 4;455(7209):58-63 - PubMed
  32. Genome Res. 2009 Jan;19(1):92-105 - PubMed
  33. Cell. 1995 Dec 15;83(6):835-9 - PubMed
  34. Prostate Cancer Prostatic Dis. 2003;6(1):27-33 - PubMed
  35. Cancer Res. 2011 Mar 1;71(5):1956-67 - PubMed
  36. Prostate. 1989;14(2):103-15 - PubMed
  37. Cancer Res. 2006 Nov 1;66(21):10613-20 - PubMed
  38. Mol Endocrinol. 1998 Oct;12(10):1558-66 - PubMed
  39. Cell. 1993 Dec 3;75(5):843-54 - PubMed
  40. Nature. 2008 Sep 4;455(7209):64-71 - PubMed
  41. Nat Rev Cancer. 2001 Oct;1(1):34-45 - PubMed
  42. Cancer Res. 2009 Oct 15;69(20):8141-9 - PubMed
  43. Dev Biol. 2007 Oct 15;310(2):442-53 - PubMed
  44. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8 - PubMed
  45. Mol Endocrinol. 1988 Dec;2(12):1265-75 - PubMed
  46. Biochem Biophys Res Commun. 1988 May 31;153(1):241-8 - PubMed
  47. Cancer Res. 1997 Jan 15;57(2):314-9 - PubMed
  48. Cancer Res. 2009 Mar 15;69(6):2305-13 - PubMed
  49. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  50. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  51. Cell Mol Life Sci. 2011 Dec;68(24):3971-81 - PubMed
  52. Cancer Res. 2007 Jul 1;67(13):6130-5 - PubMed
  53. Nat Immunol. 2008 Apr;9(4):405-14 - PubMed
  54. J Urol. 2004 Sep;172(3):1140-4 - PubMed
  55. J Biol Chem. 2007 Aug 10;282(32):23716-24 - PubMed
  56. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9 - PubMed
  57. Mol Cell Biol. 2006 Nov;26(21):8191-201 - PubMed
  58. Cancer Res. 2002 Feb 15;62(4):1008-13 - PubMed
  59. J Biol Chem. 2000 Jul 7;275(27):20853-60 - PubMed
  60. Annu Rev Biochem. 1994;63:25-61 - PubMed
  61. Cancer Res. 1987 Sep 1;47(17):4736-9 - PubMed
  62. Dev Biol. 2007 Feb 1;302(1):1-12 - PubMed
  63. Cancer Cell Int. 2009 Aug 12;9:21 - PubMed
  64. J Cell Biochem. 2004 Feb 15;91(3):483-90 - PubMed
  65. RNA. 2008 Mar;14 (3):417-24 - PubMed
  66. Trends Mol Med. 2009 Sep;15(9):381-90 - PubMed
  67. J Clin Oncol. 2003 Jan 15;21(2):383-91 - PubMed
  68. Br J Cancer. 2003 Aug 4;89(3):552-6 - PubMed
  69. Vitam Horm. 2005;71:301-19 - PubMed
  70. Hematol Oncol Clin North Am. 1996 Jun;10(3):713-25 - PubMed
  71. Int J Cancer. 2011 Aug 15;129(4):810-9 - PubMed

Publication Types

Grant support